Molecular mechanisms of drug resistance in natural leishmania populations vary with genetic background

PLoS Neglected Tropical Diseases

Volumn 6, Issue 2, 2012, Pages

  Decuypere, Saskia ^a,b,c   Vanaerschot, Manu ^a   Brunker, Kirstyn ^b   Imamura, Hideo ^a,d   Müller, Sylke ^c   Khanal, Basudha ^e   Rijal, Suman ^e   Dujardin, Jean Claude ^a,f   Coombs, Graham H ^b  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e B P KOIRALA INSTITUTE OF HEALTH SCIENCES   (Nepal)

^f UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3 MERCAPTOPYRUVATE SULFURTRANSFERASE; ANTIMONY; ANTIMONY TARTRATE; CYSTATHIONINE BETA SYNTHASE; CYSTEINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; HYDROGEN PEROXIDE; N ACETYL S NITROSOPENICILLAMINE; STIBOGLUCONATE SODIUM; SULFURTRANSFERASE; THIOL; TRYPANOTHIONE; TRYPANOTHIONE REDUCTASE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; PROTOZOAL DNA; PROTOZOAL PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENOTYPING TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PROMASTIGOTE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CHILD; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENETICS; ISOLATION AND PURIFICATION; NEPAL; PARASITOLOGY; PRESCHOOL CHILD; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETIC VARIATION; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; NEPAL; PROTOZOAN PROTEINS;

EID: 84857852404     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001514     Document Type: Article

References (76)

1. Murray HW, (2004) Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2: 279-292.
2. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
3. Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, et al. (2007) Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res 101: 1319-1322.
4. Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, et al. (2006) Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J Infect Dis 193: 1375-1383.
5. Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
6. Yardley V, Ortuno N, Llanos-Cuentas A, Chappuis F, De Doncker S, et al. (2006) American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194: 1168-1175.
7. Lira R, Sundar S, Makharia A, Kenney R, Gam A, et al. (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180: 564-567.
8. Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, et al. (2007) Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529-535.
9. Dube A, Singh N, Sundar S, Singh N, (2005) Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 96: 216-223.
10. Mookerjee BJ, Mookerjee A, Sen P, Bhaumik S, Sen P, et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-1797.
11. Rais S, Perianin A, Lenoir M, Sadak A, Rivollet D, et al. (2000) Sodium stibogluconate (Pentostam) potentiates oxidant production in murine visceral leishmaniasis and in human blood. Antimicrob Agents Chemother 44: 2406-2410.
12. Wyllie S, Cunningham ML, Fairlamb AH, (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279: 39925-39932.
13. Mehta A, Shaha C, (2006) Mechanism of metalloid-induced death in Leishmania spp.: role of iron, reactive oxygen species, Ca2+, and glutathione. Free Radic Biol Med 40: 1857-1868.
14. Baiocco P, Colotti G, Franceschini S, Ilari A, (2009) Molecular basis of antimony treatment in leishmaniasis. J Med Chem 52: 2603-2612.
15. Laurent T, Rijal S, Yardley V, Croft S, De Doncker S, et al. (2007) Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infect Genet Evol 7: 206-212.
16. Downing T, Imamura H, Decuypere S, Clark TG, Coombs GH, et al. (2011) Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res 21 (12): 2143-2156.
17. Downing T, Stark O, Vanaerschot M, Imamura H, Sanders M, et al. (2011) Genome-wide SNP and microsatellite variation unravel population-level Leishmania donovani species complex epidemiology. Infect Genet Evol Epub Nov 20.
18. Vergnes B, Gourbal B, Girard I, Sundar S, Drummelsmith J, et al. (2007) A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics 6: 88-101.
19. Singh R, Kumar D, Duncan RC, Nakhasi HL, Salotra P, (2010) Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites. Int J Antimicrob Agents 36: 50-57.
20. Singh N, Almeida R, Kothari H, Kumar P, Mandal G, et al. (2007) Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology 134: 777-787.
21. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mandal D, et al. (2011) Characterisation of Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. International Journal of Parasitology 41 (13-14): 1311-1321.
22. Samant M, Sahasrabuddhe AA, Singh N, Gupta SK, Sundar S, et al. (2007) Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani. Parasitology 134: 1175-1184.
23. Mukherjee A, Padmanabhan PK, Singh S, Roy G, Girard I, et al. (2007) Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother 59: 204-11.
24. Mandal S, Maharjan M, Singh S, Chatterjee M, Madhubala R, (2010) Assessing aquaglyceroporin gene status and expression profile in antimony-susceptible and-resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother 65: 496-507.
25. Maharjan M, Singh S, Chatterjee M, Madhubala R, (2008) Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani. Am J Trop Med Hyg 79: 69-75.
26. Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, et al. (2005) Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy. Parasitology 131: 747-757.
27. Mandal G, Wyllie S, Singh N, Sundar S, Fairlamb AH, et al. (2007) Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony. Parasitology 134: 1-9.
28. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, et al. (2010) Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol 173: 162-164.
29. Mittal MK, Rai S, Ashutosh, Ravinder, Gupta S, et al. (2007) Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76: 681-688.
30. Tintaya KW, Ying X, Dedet JP, Rijal S, De Bolle X, et al. (2004) Antigen genes for molecular epidemiology of leishmaniasis: polymorphism of cysteine proteinase B and surface metalloprotease glycoprotein 63 in the Leishmania donovani complex. J Infect Dis 189: 1035-1043.
31. Van Meirvenne N, Janssens PG, Magnus E, Lumsden WH, Herbert WJ, (1975) Antigenic variation in syringe passaged populations of Trypanosoma (Trypanozoon) brucei. II. Comparative studies on two antigenic-type collections. Ann Soc Belg Med Trop 55: 25-30.
32. Vanaerschot M, De Doncker S, Rijal S, Maes L, Dujardin JC, et al. (2011) Antimonial resistance in Leishmania donovani is associated with increased in vivo parasite burden. PLoS One 6: e23120.
33. Mottram JC, Robertson CD, Coombs GH, Barry JD, (1992) A developmentally regulated cysteine proteinase gene of Leishmania mexicana. Mol Microbiol 6: 1925-1932.
34. Decuypere S, Vanaerschot M, Rijal S, Yardley V, Maes L, et al. (2008) Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation. Parasitology 135: 183-194.
35. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, (2007) qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol 8: R19.
36. Munday JC, (2008) Studies on Oligopeptidase B of Leishmania major. [dissertation]. University of Glasgow, UK.
37. Shim H, Fairlamb AH, (1988) Levels of polyamines, glutathione and glutathione-spermidine conjugates during growth of the insect trypanosomatid Crithidia fasciculata. J Gen Microbiol 134: 807-817.
38. Mikus J, Steverding D, (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48: 265-269.
39. Cunningham ML, Fairlamb AH, (1995) Trypanothione reductase from Leishmania donovani. Purification, characterisation and inhibition by trivalent antimonials. Eur J Biochem 230: 460-468.
40. Muller S, Liebau E, Walter RD, Krauth-Siegel RL, (2003) Thiol-based redox metabolism of protozoan parasites. Trends Parasitol 19: 320-328.
41. Ariyanayagam MR, Fairlamb AH, (2001) Ovothiol and trypanothione as antioxidants in trypanosomatids. Mol Biochem Parasitol 115: 189-198.
42. da Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L, (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53: 5197-5203.
43. Debrabant A, Joshi MB, Pimenta PF, Dwyer DM, (2004) Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol 34: 205-217.
44. Adaui V, Castillo D, Zimic M, Gutierrez A, Decuypere S, et al. (2011) Comparative gene expression analysis throughout the life cycle of Leishmania braziliensis: diversity of expression profiles among clinical isolates. PLoS Negl Trop Dis 5: e1021.
45. Alcolea PJ, Alonso A, Gomez MJ, Moreno I, Dominguez M, et al. (2010) Transcriptomics throughout the life cycle of Leishmania infantum: high down-regulation rate in the amastigote stage. Int J Parasitol 40: 1497-1516.
46. Krauth-Siegel RL, Meiering SK, Schmidt H, (2003) The parasite-specific trypanothione metabolism of trypanosoma and leishmania. Biol Chem 384: 539-549.
47. Romao PR, Fonseca SG, Hothersall JS, Noronha-Dutra AA, Ferreira SH, et al. (1999) Glutathione protects macrophages and Leishmania major against nitric oxide-mediated cytotoxicity. Parasitology 118 (Pt 6): 559-566.
48. Dumas C, Ouellette M, Tovar J, Cunningham ML, Fairlamb AH, et al. (1997) Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 16: 2590-2598.
49. Kelly JM, Taylor MC, Smith K, Hunter KJ, Fairlamb AH, (1993) Phenotype of recombinant Leishmania donovani and Trypanosoma cruzi which over-express trypanothione reductase. Sensitivity towards agents that are thought to induce oxidative stress. Eur J Biochem 218: 29-37.
50. Tovar J, Wilkinson S, Mottram JC, Fairlamb AH, (1998) Evidence that trypanothione reductase is an essential enzyme in Leishmania by targeted replacement of the tryA gene locus. Mol Microbiol 29: 653-660.
51. Ait-Oudhia K, Gazanion E, Oury B, Vergnes B, Sereno D, (2011) The fitness of antimony-resistant Leishmania parasites: lessons from the field. Trends Parasitol 27: 141-142.
52. Perry MR, Wyllie S, Prajapati VK, Feldmann J, Sundar S, et al. (2011) Visceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian Subcontinent? PLoS Negl Trop Dis 5 (9): e1227.
53. Sidhu AB, Valderramos SG, Fidock DA, (2005) pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol 57: 913-926.
54. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944-1946.
55. Weinreich DM, Watson RA, Chao L, (2005) Perspective: Sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59: 1165-1174.
56. Beerenwinkel N, Knupfer P, Tresch A, (2011) Learning monotonic genotype-phenotype maps. Stat Appl Genet Mol Biol 10 In press.
57. Borrell S, Gagneux S, (2011) Strain diversity, epistasis and the evolution of drug resistance in Mycobacterium tuberculosis. Clin Microbiol Infect 17: 815-820.
58. Alvar J, Croft S, Olliaro P, (2006) Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61: 223-274.
59. Ashutosh, Sundar S, Goyal N, (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143-153.
60. Nozaki T, Shigeta Y, Saito-Nakano Y, Imada M, Kruger WD, (2001) Characterization of transsulfuration and cysteine biosynthetic pathways in the protozoan hemoflagellate, Trypanosoma cruzi. Isolation and molecular characterization of cystathionine beta-synthase and serine acetyltransferase from Trypanosoma. J Biol Chem 276: 6516-6523.
61. Williams RA, Kelly SM, Mottram JC, Coombs GH, (2003) 3-Mercaptopyruvate sulfurtransferase of Leishmania contains an unusual C-terminal extension and is involved in thioredoxin and antioxidant metabolism. J Biol Chem 278: 1480-1486.
62. Grondin K, Haimeur A, Mukhopadhyay R, Rosen BP, Ouellette M, (1997) Co-amplification of the gamma-glutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae. EMBO J 16: 3057-3065.
63. Fairlamb AH, Cerami A, (1992) Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 46: 695-729.
64. Flohe L, Hecht HJ, Steinert P, (1999) Glutathione and trypanothione in parasitic hydroperoxide metabolism. Free Radic Biol Med 27: 966-984.
65. Krauth-Siegel RL, Bauer H, Schirmer RH, (2005) Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia. Angew Chem Int Ed Engl 44: 690-715.
66. Brochu C, Wang J, Roy G, Messier N, Wang XY, et al. (2003) Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother 47: 3073-3079.
67. Gourbal B, Sonuc N, Bhattacharjee H, Legare D, Sundar S, et al. (2004) Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem 279: 31010-31017.
68. Ferreira CS, Martins PS, Demicheli C, Brochu C, Ouellette M, et al. (2003) Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 16: 441-446.
69. Frezard F, Demicheli C, Ferreira CS, Costa MA, (2001) Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate. Antimicrob Agents Chemother 45: 913-916.
70. Yan S, Li F, Ding K, Sun H, (2003) Reduction of pentavalent antimony by trypanothione and formation of a binary and ternary complex of antimony(III) and trypanothione. J Biol Inorg Chem 8: 689-697.
71. Yan S, Wong IL, Chow LM, Sun H, (2003) Rapid reduction of pentavalent antimony by trypanothione: potential relevance to antimonial activation. Chem Commun (Camb) pp. 266-267.
72. Denton H, McGregor JC, Coombs GH, (2004) Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 381: 405-412.
73. Zhou Y, Messier N, Ouellette M, Rosen BP, Mukhopadhyay R, (2004) Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J Biol Chem 279: 37445-37451.
74. Legare D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, et al. (2001) The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 276: 26301-26307.
75. Coelho AC, Beverley SM, Cotrim PC, (2003) Functional genetic identification of PRP1, an ABC transporter superfamily member conferring pentamidine resistance in Leishmania major. Mol Biochem Parasitol 130: 83-90.
76. Dey S, Ouellette M, Lightbody J, Papadopoulou B, Rosen BP, (1996) An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci U S A 93: 2192-2197.